6/10/2013

The FDA has given Gilead Sciences' experimental hepatitis C drug sofosbuvir priority review status. The drug has demonstrated a high cure rate for patients with infection genotypes 2 and 3 and better efficacy than interferon.

Full Story:
Medical News Today

Related Summaries